Skip to main content

Advertisement

Table 1 Summary result of therapeutic efficacy study in six sentinel sites in Myanmar (2009–2013)

From: Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Description Kawthaung Myawaddy TBZ Shwegyin Rakhine Magway
Year 2009 2009 2010 2012 2013 2010 2012 2013 2010 2009 2009 2012 2013 2010 2010 2012
Drug DP AL AL AL AM AL AL DP DP DP AL AL DP AL DP AL
Recruited cases 80 80 85 58 48 75 59 68 83 72 86 51 39 81 80 115
Treatment failure 4 6 5 0 0 4 2 3 2 0 2 3 1 3 1 0
LFU 0 0 1 0 0 1 0 0 5 0 0 1 0 0 0 0
Day 1 parasite positivity (n, %) 76 (95.0) 52 (65.0) 75 (89.3) 47 (81.0) 40 (83.3) 61 (82.4) 39 (66.1) 52 (76.5) 76 (97.4) 51 (70.8) 72 (83.7) 9 (18.0) 11 (28.2) 31 (38.3) 39 (48.8) 81 (70.4)
Day 2 parasite positivity (n, %) 54 (67.5) 30 (37.5) 38 (45.2) 12 (20.7) 23 (47.9) 22 (29.7) 15 (25.4) 16 (23.5) 44 (56.4) 15 (20.8) 30 (34.9) 2 (4.0) 1 (2.6) 1 (1.2) 3 (3.8) 31 (27.0)
Day 3 parasite positivity (n, %) 15 (18.7) 5 (6.3) 7 (8.3) 7 (12.1) 5 (10.4) 3 (4.1) 8 (13.6) 4 (5.9) 17 (20.5) 3 (4.2) 8 (9.3) 3 (6.0) 5 (12.8) 0 (0.0) 0 (0.0) 0 (0.0)
ACPR (n, %) 76 (95.0) 74 (92.5) 79 (94.0) 58 (100.0) 48 (100.0) 70 (94.6) 57 (96.6) 65 (95.6) 76 (97.4) 72 (100.0) 84 (97.7) 47 (94.0) 38 (97.4) 78 (96.3) 79 (98.7) 115 (100.0)
Recrudescence 2 6 2 0 0 1 2 3 1 0 0 1 0 0 0 0
Reinfection 1 0 2 0 0 2 0 0 1 0 1 1 1 3 1 0
  1. TBZ Thanbyuzayat, DP dihydroartemisinin–piperaquine, AL artemether–lumefantrine, LFU loss to follow-up, ACPR adequate clinical and parasitological response, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure